Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Merck Tbk's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was Rp84,323 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was Rp395,487 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
PT Merck Tbk's annualizedROC % for the quarter that ended in Mar. 2026 was 33.23%.
PT Merck Tbk's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 63.24%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
PT Merck Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 31.39%.
PT Merck Tbk (ISX:MERK) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
PT Merck Tbk's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Merck Tbk EBIT Related Terms
PT Merck Tbk EBIT Historical Data
* Premium members only.
The historical data trend for PT Merck Tbk's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PT Merck Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Merck Tbk EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Merck Tbk's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PT Merck Tbk's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp395,487 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Merck Tbk (ISX:MERK) has a EBIT of Rp395,487 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Merck Tbk.
Is PT Merck Tbk's EBIT too high?
PT Merck Tbk's current EBIT is Rp395,487 Mil. Overall, PT Merck Tbk has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Merck Tbk's EBIT compare to ZTS and UTHR?
PT Merck Tbk's EBIT of Rp395,487 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Merck Tbk. PT Merck Tbk's current EBIT is Rp395,487 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Merck Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Merck Tbk (ISX:MERK) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp4,944.61, compared to a current price of Rp3,760.00 — trading 24% below its estimated fair value. The current EBIT is Rp395,487 Mil. PT Merck Tbk's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For PT Merck Tbk (ISX:MERK), the current EBIT is Rp395,487 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Merck Tbk (ISX:MERK) Overvalued in 2026?
Based on GuruFocus' analysis, PT Merck Tbk stock appears to be undervalued.
The current stock price of Rp3,760.00 is trading 24% below its estimated GF Value™ of Rp4,944.61.
GuruFocus considers PT Merck Tbk to be Modestly Undervalued.
Key valuation signals for ISX:MERK:
EBIT: Rp395,487 Mil
GF Value™: Rp4,944.61 vs. price of Rp3,760.00 (24% below fair value)
No single metric tells the full story. See the ISX:MERK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.
84GF Score
Get the complete analysis for ISX:MERK
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:MERK has been successfully added to your 
